134 related articles for article (PubMed ID: 16316482)
21. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials.
Goodman WK; Bose A; Wang Q
J Affect Disord; 2005 Aug; 87(2-3):161-7. PubMed ID: 15982747
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
Chauvet-Gélinier JC
Encephale; 2010 Oct; 36(5):425-32. PubMed ID: 21035633
[TBL] [Abstract][Full Text] [Related]
23. Escitalopram in the treatment of social anxiety disorder: analysis of efficacy for different clinical subgroups and symptom dimensions.
Stein DJ; Kasper S; Andersen EW; Nil R; Lader M
Depress Anxiety; 2004; 20(4):175-81. PubMed ID: 15643634
[TBL] [Abstract][Full Text] [Related]
24. Factors predicting relapse in elderly patients with major depressive disorder treated with escitalopram in an outpatient setting.
Dolberg O; Larsson Lönn S; Kvist K
Curr Med Res Opin; 2014 Jul; 30(7):1301-7. PubMed ID: 24628498
[TBL] [Abstract][Full Text] [Related]
25. Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder.
Baldwin DS; Loft H; Florea I
Int Clin Psychopharmacol; 2012 Jul; 27(4):197-207. PubMed ID: 22475889
[TBL] [Abstract][Full Text] [Related]
26. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study.
Bandelow B; Chouinard G; Bobes J; Ahokas A; Eggens I; Liu S; Eriksson H
Int J Neuropsychopharmacol; 2010 Apr; 13(3):305-20. PubMed ID: 19691907
[TBL] [Abstract][Full Text] [Related]
27. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
Colonna L; Andersen HF; Reines EH
Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.
Rynn M; Russell J; Erickson J; Detke MJ; Ball S; Dinkel J; Rickels K; Raskin J
Depress Anxiety; 2008; 25(3):182-9. PubMed ID: 17311303
[TBL] [Abstract][Full Text] [Related]
29. Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.
Schaefer M; Sarkar R; Knop V; Effenberger S; Friebe A; Heinze L; Spengler U; Schlaepfer T; Reimer J; Buggisch P; Ockenga J; Link R; Rentrop M; Weidenbach H; Fromm G; Lieb K; Baumert TF; Heinz A; Discher T; Neumann K; Zeuzem S; Berg T
Ann Intern Med; 2012 Jul; 157(2):94-103. PubMed ID: 22801672
[TBL] [Abstract][Full Text] [Related]
30. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study.
Brown ES; Howard C; Khan DA; Carmody TJ
Psychosomatics; 2012; 53(1):75-80. PubMed ID: 22221724
[TBL] [Abstract][Full Text] [Related]
31. Escitalopram in the treatment of anxiety symptoms associated with depression.
Bandelow B; Andersen HF; Dolberg OT
Depress Anxiety; 2007; 24(1):53-61. PubMed ID: 16937393
[TBL] [Abstract][Full Text] [Related]
32. A randomized, double-blind, placebo-controlled study of escitalopram in patients with social anxiety disorder in Japan.
Asakura S; Hayano T; Hagino A; Koyama T
Curr Med Res Opin; 2016; 32(4):749-57. PubMed ID: 26808688
[TBL] [Abstract][Full Text] [Related]
33. The effect of escitalopram on sleep problems in depressed patients.
Lader M; Andersen HF; Baekdal T
Hum Psychopharmacol; 2005 Jul; 20(5):349-54. PubMed ID: 15912558
[TBL] [Abstract][Full Text] [Related]
34. Pharmacotherapy Relapse Prevention in Body Dysmorphic Disorder: A Double-Blind, Placebo-Controlled Trial.
Phillips KA; Keshaviah A; Dougherty DD; Stout RL; Menard W; Wilhelm S
Am J Psychiatry; 2016 Sep; 173(9):887-95. PubMed ID: 27056606
[TBL] [Abstract][Full Text] [Related]
35. Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine.
Boulenger JP; Hermes A; Huusom AK; Weiller E
Curr Med Res Opin; 2010 Mar; 26(3):605-14. PubMed ID: 20067433
[TBL] [Abstract][Full Text] [Related]
36. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
Fava M; Asnis GM; Shrivastava RK; Lydiard B; Bastani B; Sheehan DV; Roth T
J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597
[TBL] [Abstract][Full Text] [Related]
37. Superiority of escitalopram to paroxetine in the treatment of depression.
Kasper S; Baldwin DS; Larsson Lönn S; Boulenger JP
Eur Neuropsychopharmacol; 2009 Apr; 19(4):229-37. PubMed ID: 19185467
[TBL] [Abstract][Full Text] [Related]
38. 12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder.
Stein DJ; Khoo JP; Ahokas A; Jarema M; Van Ameringen M; Vavrusova L; Hӧschl C; Bauer M; Bitter I; Mosolov SN; Olivier V; Matharan S; Picarel-Blanchot F; de Bodinat C
Eur Neuropsychopharmacol; 2018 Aug; 28(8):970-979. PubMed ID: 30135032
[TBL] [Abstract][Full Text] [Related]
39. Escitalopram prevents relapse of obsessive-compulsive disorder.
Fineberg NA; Tonnoir B; Lemming O; Stein DJ
Eur Neuropsychopharmacol; 2007; 17(6-7):430-9. PubMed ID: 17240120
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of escitalopram for generalized anxiety disorder in Canada.
Iskedjian M; Walker JH; Bereza BG; Le Melledo JM; Einarson TR
Curr Med Res Opin; 2008 May; 24(5):1539-48. PubMed ID: 18416886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
